Drug Safety in the Limelight

FDA resolves the bar code labeling debate, releases its GMP requirements for dietary supplements, and proposes a comprehensive adverse-event reporting system.

Related Content:

Regulatory WatchPharmaceutical Technology-05-02-2003

Biosimilars Move to Center Stage

CMA Fines Advanz for Over-Pricing Liothyronine Tablets

FDA Prioritizes Vaccine Review and Process Improvements